Lung Cancer

Median overall survival was also 2 months less for patients with extensive-stage small cell lung cancer who were ineligible for clinical trials.

The KEYNOTE-641 and -789 trials did not demonstrate improvements or meet the primary endpoints in metastatic castration-resistant prostate cancer and metastatic nonsquamous non–small cell lung cancer.

Ventana PD-L1 (SP263) Assay can increase access to cemiplimab and improve patient outcomes in non-small cell lung cancer.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

Pembrolizumab showed statistically significant improvement in the event-free survival of patients with resectable stage 2 or 3 non-small cell lung cancer.

An expert shares information on risk factors and controversies around testing.

Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.

Investigators hope that new findings can cultivate new methods of facilitating immune response to attack lung tumors.

In the United States, 91% of states had lower rates of targeted therapy use than expected.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

Overall survival data were immature at the time of interim analysis and follow-up will continue to the next analysis.

The biopsy test is the first companion diagnostic approved for entrectinib for individuals who do not have an available tissue sample.

Significant advancements have changed the treatment landscape and clinical practice procedures.

The additional indication expands its therapeutic role beyond advanced non-small cell lung cancer.

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

Future research should investigate which therapies with new mechanisms of action add incremental benefit to existing treatment regimens for non-small cell lung cancer.

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

Biomarker testing and management of immune-related adverse events are key roles for pharmacists.

Scott Soefje, director of Pharmacy Cancer Care and assistant professor of Pharmacy at Mayo Clinic, discusses the role of PD-1 inhibitors in treating non–small cell lung cancer.

Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.

Patients with lung cancer in an early-intervention lung screening program were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.

The objective of the study was to estimate recent trends in cigarette use and health insurance coverage for US adults with and without mental health and SUD.

Under specific circumstances and criteria, they are adjustable to approximate OS in selected populations of Canadian patients who have advanced non–small cell lung cancer.

Tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy approved for the treatment of adults with metastatic non–small cell lung cancer without sensitizing EGFR mutation or ALK aberrations.

Improvement is seen with a higher suspicion of disease and extended timelines, analysis demonstrates.

Efficacy results comparing the cemiplimab-rwlc combination to chemotherapy alone showed a 22-month median overall survival versus 13 months.

In the inpatient acute care setting, oncology pharmacists maximize return on investments of oncology products, produce optimal outcomes, and ensure that quality of care is consistent and safe.

By 2019, lung cancer mortality rates decreased by 5.4% in males since 2015, while deaths from ovary cancer have also declined rapidly over the past 2 decades.

In a multivariable analysis, treatment with carboplatin is favored for extensive-stage cell lung cancer, even if it is not found to increase overall survival compared to standard care.

The study will evaluate the safety, tolerability, and efficacy of the in combination in patients both with and without prior exposure to a KRASG12C inhibitor.